HHU.F ALLERGY THER. PLC LS-001

Healthcare Pharmaceuticals Frankfurt Exchange
0.0091 EUR
Close of Nov 12, 2026
0.0065 0.1320
Market cap
EUR 57.5M
P/E
-
P/B
9.98x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2025.

Is HHU.F undervalued?

Graham number

The Graham number of ALLERGY THER. PLC LS-001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ALLERGY THER. PLC LS-001 fundamental analysis

No fundamental analysis for ALLERGY THER. PLC LS-001 yet.

ALLERGY THER. PLC LS-001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ALLERGY THER. PLC LS-001

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venom…

Full company profile